1-3 of 3
Oskar Pichelmayer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD
Journal: Blood
Blood (2007) 110 (11): 2578.
https://doi.org/10.1182/blood.V110.11.2578.2578
Published: 2007
Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD
Journal: Blood
Blood (2006) 108 (11): 2753.
https://doi.org/10.1182/blood.V108.11.2753.2753
Published: 2006
Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD
Journal: Blood
Blood (2005) 106 (11): 4799.
https://doi.org/10.1182/blood.V106.11.4799.4799
Published: 2005